Tito has served in the field of in vitro diagnostics for over 35 years and has a proven track record of repeatedly and successfully turning innovative technology into revenue-generating platforms. Currently, he is CEO of PredictImmune Limited, a predictive medicine company he spun out of Cambridge University.

He has held senior executive positions at EKF (2014-2016), J&J (2005-2013) and Ares-Serono (1998 – 2008) and has cofounded several start-ups in the diagnostic arena. He is a Fellow of the American Association of Clinical Biochemistry and has published more than 50 peer-reviewed articles on a variety of topics related to pathology, oncology and laboratory medicine.

He graduated from King’s College, London and earned his PhD at the Royal Postgraduate Medical Centre in London.